‘Heparin rebound’ means the opposite in cardiac surgery (bleeding) and in cardiology (thrombosis)

Koraćević, Goran

doi:10.1097/mbc.0b013e3283370126

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5. Rebound syndromes have been reported after a sudden withdrawal of various drugs used in cardiology, starting from heparin rebound and beta blocker (BB) rebound (14,(17)(18)(19)(20)(21)(22)(23)(24)(25).…”

Section: Literature Overviewmentioning

confidence: 99%

Rebound Phenomenon – Important and Ubiquitous in Pharmacotherapy

Koraćević¹,

Lalić²,

Nedeljković³

et al. 2018

AMM

View full text Add to dashboard Cite

The rebound effect represents a common characteristic of the numerous classes of modern drugs and can result in serious and even fatal disorders. For example, prolonged administration of proton pump inhibitor (PPI) leads to moderate hypergastrinemia in 20-25%. This hypergastrinemia will result in rebound gastric acid hypersecretion in 30-40% of patients following the abrupt PPI discontinuation. PPIs are among the most widely used drugs worldwide.An abrupt cessation of chronic corticosteroid, beta blocker, or opioid treatment may also provoke rebound phenomenon. Even in heart failure patients, beta blocker withdrawal on admission resulted in a significant increase of the probability of in-hospital mortality. The incidence of a rebound phenomenon depends on numerous factors, including the intensity and duration of action of a particular drug and how long it has been applied; the susceptibility of an individual patient (regarding the comorbidities and the severity of the primary disease) and the related circumstances (e.g, co-therapy). The clinical importance of the rebound phenomenon varies from academic to lethal. Even rare rebounds found for some classes of drugs are becoming very important if the drug has been used often globally. Acta Medica Medianae 2018;57(4):148-152.

show abstract

Section: Literature Overviewmentioning

confidence: 99%

Rebound Phenomenon – Important and Ubiquitous in Pharmacotherapy

Koraćević¹,

Lalić²,

Nedeljković³

et al. 2018

AMM

View full text Add to dashboard Cite

show abstract

“…The risk is indeed very low in obstetric patients receiving LMWH, so routine platelet monitoring is not recommended 7, 68-71 . One further advantage of LMWH over UFH is significantly less procoagulant "rebound effect" after withdrawal of the therapy 73,74 . This problem may be resolved by switching to another LMWH preparation or danaparoid or fondaparinux 1, 72 .…”

Section: Medication Options For Thromboprophylaxis In Pregnancy and Pmentioning

confidence: 99%